Clinical pharmacokinetics of new antiepileptic drugs.

Article Details

Citation
Copy to clipboard

Walker MC, Patsalos PN

Clinical pharmacokinetics of new antiepileptic drugs.

Pharmacol Ther. 1995;67(3):351-84.

PubMed ID
8577822 [ View in PubMed
]
Abstract

We have reviewed the pharmacokinetics of six antiepileptic drugs that are marketed (felbamate, gabapentin, lamotrigine, oxcarbazepine, vigabatrin, and zonisamide) and six drugs that are undergoing evaluation (levetiracetam, ralitoline, remacemide, stiripentol, tiagabine, and topiramate). In addition, we have compared the prodrugs eterobarb and fosphenytoin and the controlled-release formulations of valproic acid and carbamazepine with their parent compounds. Finally, we have devised a scoring system to compare the pharmacokinetics of new antiepileptic drugs. Using this system, vigabatrin, levetiracetam, gabapentin, and topiramate appea to have the most favourable pharmacokinetic profiles, whilst ralitoline and stiripentol have the least favourable.

DrugBank Data that Cites this Article

Drug Carriers
DrugCarrierKindOrganismPharmacological ActionActions
FosphenytoinSerum albuminProteinHumans
No
Other/unknown
Details